Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia

NCT05943314 · clinicaltrials.gov ↗

NA

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped The clinical trial was terminated due to a change in sponsor strategy.

Conditions

Acute Myeloid Leukemia

Interventions

BIOLOGICAL: CLL1/+CD33 CAR-T

Sponsor

Guangzhou Bio-gene Technology Co., Ltd